HSM Helius Medical Technologies Inc

Helius Medical Technologies, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Helius Medical Technologies, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NEWTOWN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the H.C. Wainwright Annual Global LifeSciences Conference, which is being held virtually from September 13th-15th. Management’s presentation will be available on-demand beginning on Monday, September 13th at 7:00 a.m. Eastern Time. Management will participate in investor meetings throughout the duration of the conference.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform including the Portable Neuromodulation Stimulator (PoNS™). For more information, visit .

About the PoNS™ Device and PoNS Treatment™

The Portable Neuromodulation Stimulator (PoNS™) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the Australia (“AUS”) and is currently under premarket review by the AUS Therapeutic Goods Administration.

Investor Relations Contact:

Westwicke on behalf of Helius Medical Technologies, Inc.

Jack Powell, Vice President

 



EN
07/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Helius Medical Technologies Inc

 PRESS RELEASE

CORRECTION – Solana Company Announces Updated SOL Holdings and Industr...

CORRECTION – Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Wednesday, October 29th by Solana Company (NASDAQ: HSDT), please note that in the first sentence of the third paragraph, the increase of the amount of "SOL" held should be roughly 0.1 million, not 1 million. The corrected release follows:  Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”) today announced its updated Solana (“SOL”) token and cash holdings as of Oct. 29 at 12:00 am ET, as well as i...

 PRESS RELEASE

Solana Company Announces Updated SOL Holdings and Industry Leading Sta...

Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”) today announced its updated Solana (“SOL”) token and cash holdings as of Oct. 29 at 12:00 am ET, as well as its current staking performance. This update reflects the Company’s continued execution of its mission to maximize SOL per share through disciplined execution of its digital asset treasury strategy including capital deployment, active onchain management, and transparent reporting. As of Oct. 29, the...

 PRESS RELEASE

Solana Company Executive Chairman’s Message: October 20th, 2025

Solana Company Executive Chairman’s Message: October 20th, 2025 NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ: HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ: HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather t...

 PRESS RELEASE

Preeminent SOL Treasury Vehicle, Solana Company (NASDAQ:HSDT), Adds Co...

Preeminent SOL Treasury Vehicle, Solana Company (NASDAQ:HSDT), Adds Coinbase, BitGo, and Anchorage Digital as Custodians NEWTOWN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Solana Company, (NASDAQ:HSDT or “the Company"), formerly Helius Medical Technologies, Inc., today announced it has entered into agreements with Coinbase, BitGo and Anchorage Digital to serve as custodians as it continues amassing SOL, the native asset of the Solana Network, as part of its digital assets treasury strategy. “As HSDT continues to operate as the preeminent SOL-focused treasury, establishing relationships with...

 PRESS RELEASE

Solana Company (NASDAQ:HSDT), Formerly Helius, Continues Amassing SOL,...

Solana Company (NASDAQ:HSDT), Formerly Helius, Continues Amassing SOL, the Native Asset of Solana Blockchain NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its continued acquisition of Solana (“SOL”) tokens as part of its digital asset treasury strategy. The Company now holds over 2.2 million SOL. The Company also holds in excess of $15 million of cash, which it intends to use to further the digital asset treasury strategy. The Company’s combined Solana holdings (at $232.50 per SOL as of October 6th at 12:00AM E...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch